As reported by MarketBeat, shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report ) have received an average rating of Moderate Buy from the 13 research firms covering the company. One analyst has rated the stock with a Hold rating, while twelve have given the company a Buy rating. The average 12-month target price among brokers that have covered the company’s stock in the past year is $93.07.
A number of equities research analysts have issued reports on the company. Citigroup lowered their price objective on Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Jefferies Financial Group began covering Exact Sciences in a report on Monday, June 3rd. The firm set a “buy” rating and a $75.00 price objective for the company. BTIG Research lowered their price objective on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. The Street lowered shares of Exact Sciences from a “c-” to a “d+” rating in a research report on Monday, February 26th. Finally, Canaccord Genuity Group lowered their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th.
Check out our latest stock analysis for Exact Sciences
Exact Sciences, up 1.9%
NASDAQ EXAS opened trading at $44.85 on Friday. The company has a market cap of $8.28 billion, a P/E ratio of -33.98 and a beta of 1.26. Exact Sciences’s low in the past 12 months is $41.08 and its high in the past 12 months is $100.77. The company’s debt-to-equity ratio is 0.66, current ratio is 1.64 and quick ratio is 1.45. The company’s 50-day moving average is $52.46 and 200-day moving average is $61.01.
Exact Sciences (NASDAQ:EXAS – get free report ) released its quarterly earnings report on Wednesday, May 8th. The medical research company reported quarterly EPS of ($0.50), hitting the consensus estimate of ($0.50). Exact Sciences had a net margin of -9.48% and a return on equity of -7.12%. The company’s quarterly revenue of $637.52 million beat analyst estimates of $624.95 million. Equity analysts, as a group, expect Exact Sciences to post -1.15 earnings per share for the current fiscal year.
Insiders bet
In other news, Executive VP Sarah Condella sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70, for a total transaction value of $140,000. Following the completion of the transaction, the Executive VP now directly owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link . In related news, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction value of $69,473.25. Following the completion of the sale, the CEO now directly owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Additionally, Executive Vice President, Sarah Condella sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70, for a total value of $140,000. Following the completion of the sale, the Executive Vice President now owns 71,787 shares of the company’s stock, valued at $5,025,090. The disclosure for this sale can be found here. In the last 3 months, insiders have sold 5,498 shares of the company’s stock, valued at $370,105. 1.36% of the stock is owned by insiders.
Hedge funds move into exact sciences
A number of hedge funds have recently added to or reduced their investments in the company. Wolff Wiese Magana LLC increased its holdings in Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company worth $31,000 after purchasing an additional 340 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in Exact Sciences by 65.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company worth $31,000 after acquiring an additional 179 shares in the last quarter. Able Wealth Management LLC acquired a new holding in Exact Sciences worth approximately $45,000 in the fourth quarter. EverSource Wealth Advisors LLC increased its holdings in Exact Sciences by 92.4% in the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 340 shares in the last quarter. Finally, Valley National Advisers Inc. increased its holdings in Exact Sciences by 29.5% in the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 176 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.
Exact Sciences Company Profile
(Get your free report
Exact Sciences Corporation provides cancer screening and diagnostic testing products in the U.S. and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and precancerous conditions. The company also offers the Oncotype DX Breast Recurrence Score test, the Oncotype DX Breast DCIS Score test, the Oncotype DX Colon Recurrence Score test, the OncoExTra test, and Covid-19 testing services for tumor profiling of patients with advanced, metastatic, refractory, recurrent, or recurrent cancer.
References
Get Exact Sciences News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Exact Sciences and related companies every day with MarketBeat.com’s free email newsletter.
